Subjects who receive the Treovance stent-graft for Aneurysm

Phase-Based Progress Estimates

Effectiveness

Safety

Aneurysm+3 More

Subjects who receive the Treovance stent-graft - Device

You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.

Eligibility

18+

All Sexes

What conditions do you have?

Select

Eligibility

18+

All Sexes

What conditions do you have?

Select

Study Summary

This trial is testing a new stent-graft for people with abdominal aortic aneurysms. They want to see if it's safe and effective.

Eligible Conditions

Aneurysm
Aortic Aneurysm, Abdominal

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Aneurysm

Non-AAA Group

Metformin group

GORE® EXCLUDER® Conformable AAA Endoprosthesis

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: 12 months

12 months

Primary Efficacy

30 days

Primary Safety

Month 12

Secondary Safety Endpoint

Month 6

Secondary Efficacy Endpoint -- Device-Related Complications

Month 6

Secondary Efficacy Endpoint-- Secondary interventions

Trial Safety

Safety Progress

2 of 3

This is further along than 68% of similar trials

Other trials for Aneurysm

Non-AAA Group

Metformin group

GORE® EXCLUDER® Conformable AAA Endoprosthesis

Trial Design

1 Treatment Group

Treovance

1 of 1

Experimental Treatment

150 Total Participants · 1 Treatment Group

Primary Treatment: Subjects who receive the Treovance stent-graft · No Placebo Group · Phase 2

Treovance

Device

Experimental Group · 1 Intervention: Subjects who receive the Treovance stent-graft · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline

Screening: ~3 weeks

Treatment: Varies

Reporting: 12 months

Who is running the clinical trial?

Bolton MedicalLead Sponsor

14 Previous Clinical Trials

2,276 Total Patients Enrolled

12 Trials studying Aneurysm

2,170 Patients Enrolled for Aneurysm

Matthew Eagleton, MDPrincipal InvestigatorCleveland Clinic Foundaton

1 Previous Clinical Trials

143 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

The subject must have an infrarenal AAA that is > 4.5 cm in diameter for males, or > 4.0 cm in diameter for females, or has increased in diameter by 0.5 cm in the last 6 months.

About The Reviewer

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: October 19th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References